{"entity":{"id":"paper-ipss-m-bernard-nejm-evidence-2022","kind":"paper","name":"IPSS-M: the molecular international prognostic scoring system for myelodysplastic syndromes","aka":[],"tldr":"By adding mutations in 31 genes to blood counts and chromosomes, the IPSS-M sorts myelodysplastic syndromes into six risk groups and reclassifies about half of patients compared with the older score.","summary":"Development and validation of a prognostic model in 2,957 patients with MDS, combining clinical variables, cytogenetics and mutations in 31 genes into a continuous score with six risk categories; validated in an independent cohort of 754 patients.\n\nTP53 multi-hit, FLT3 and MLL partial tandem duplications carried the most adverse weight; SF3B1 was favourable. Compared with IPSS-R, 46 percent of patients were reclassified, most often upwards.","asOf":"2026-09-17","links":[{"label":"NEJM Evid 2022","url":"https://doi.org/10.1056/EVIDoa2200008"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/38319256/"}],"tags":[],"related":[],"cancers":["mds-higher-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm-evidence"],"dependsOn":[],"notes":[],"journal":"NEJM Evidence","year":2022,"doi":"10.1056/EVIDoa2200008","pmid":"38319256","authors":"Bernard E, Tuechler H, Greenberg PL, et al.","paperType":"methods","findings":["Six risk categories with median survival from over 10 years to about one year.","46 percent of patients reclassified compared with IPSS-R, 74 percent of those to a higher risk group."],"whatItMeans":"Sequencing at diagnosis now changes the risk group, and therefore the transplant discussion, for a large fraction of patients. Trials and guidelines are adopting the IPSS-M in place of the IPSS-R.","caveats":["Requires a broad myeloid sequencing panel that is not universally available.","Derived mostly from untreated patients at diagnosis."],"changedPractice":true,"participants":2957},"route":"/key-papers/paper-ipss-m-bernard-nejm-evidence-2022/","neighbours":{"cancer":[{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"journal":[{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/"}]}}